Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Verve Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/02/2022 |
4
| Bellinger Andrew (CSO & CMO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Sold 865 shares
@ $22.95, valued at
$19.9k
|
|
| 12/01/2022 |
4
| Dorval Allison (CFO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Sold 554 shares
@ $22.1, valued at
$12.2k
Exercised 1,875 restricted stock units
@ $0 |
|
| 11/08/2022 |
4
| Yeshwant Krishna (10% Owner) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Disposed of 48,583 shares
@ $0
Sold 47,690 shares
@ $31.118, valued at
$1.5M
Sold 650 shares
@ $31.9905, valued at
$20.8k
Sold 243 shares
@ $32.9, valued at
$8k
|
|
| 11/08/2022 |
4
| GV 2017 GP, L.L.C. (Member of 10% Group) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Disposed of 48,583 shares
@ $0
Sold 47,690 shares
@ $31.118, valued at
$1.5M
Sold 651 shares
@ $31.9905, valued at
$20.8k
Sold 242 shares
@ $32.9, valued at
$8k
Sold 47,690 shares
@ $31.118, valued at
$1.5M
Sold 650 shares
@ $31.9905, valued at
$20.8k
Sold 243 shares
@ $32.9, valued at
$8k
|
|
| 11/04/2022 |
4
| Yeshwant Krishna (10% Owner) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Disposed of 28,651 shares
@ $0
Sold 9,350 shares
@ $34.7754, valued at
$325.1k
Sold 10,372 shares
@ $36.2786, valued at
$376.3k
Sold 8,930 shares
@ $36.775, valued at
$328.4k
Disposed of 49,569 shares
@ $0
Sold 22,279 shares
@ $32.3155, valued at
$720k
Sold 25,534 shares
@ $33.1384, valued at
$846.2k
Sold 1,755 shares
@ $33.8373, valued at
$59.4k
|
|
| 11/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/27/2022 |
4
| Bellinger Andrew (CSO & CMO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Sold 6,632 shares
@ $34.666, valued at
$229.9k
Sold 13,368 shares
@ $35.5927, valued at
$475.8k
Sold 36,798 shares
@ $35.3091, valued at
$1.3M
Sold 3,202 shares
@ $36.0336, valued at
$115.4k
Exercised 40,000 options to buy
@ $1.48, valued at
$59.2k
Exercised 20,000 options to buy
@ $1.48, valued at
$29.6k
|
|
| 08/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/11/2022 |
4
| Kathiresan Sekar (CEO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Sold 50,000 shares
@ $29.9, valued at
$1.5M
Exercised 50,000 options to buy
@ $1.39, valued at
$69.5k
|
|
| 08/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/22/2022 |
4
| Bellinger Andrew (CSO & CMO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Sold 20,000 shares
@ $34.9, valued at
$698k
Exercised 20,000 options to buy
@ $1.39, valued at
$27.8k
|
|
| 07/21/2022 |
4
| Kathiresan Sekar (CEO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Sold 50,000 shares
@ $29.9, valued at
$1.5M
Exercised 50,000 options to buy
@ $1.39, valued at
$69.5k
|
|
| 07/15/2022 |
4
| Kathiresan Sekar (CEO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Gifted 160,000 shares
@ $0
Gifted 160,000 shares
@ $0
Gifted 140,000 options to buy
@ $8.24, valued at
$1.2M
Gifted 160,000 options to buy
@ $2.87, valued at
$459.2k
Gifted 140,000 options to buy
@ $8.24, valued at
$1.2M
Gifted 160,000 options to buy
@ $2.87, valued at
$459.2k
|
|
| 07/15/2022 |
4
| Bellinger Andrew (CSO & CMO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Sold 10,000 shares
@ $24.9, valued at
$249k
Exercised 10,000 options to buy
@ $1.48, valued at
$14.8k
|
|
| 07/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Mikhail Sheila (Director) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Granted 15,500 options to buy
@ $14.04, valued at
$217.6k
|
|
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/22/2022 |
4
| Kathiresan Sekar (CEO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Exercised 69,674 options to buy
@ $2.87, valued at
$200k
|
|
| 03/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/11/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2022 |
4
| Dorval Allison (CFO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Granted 60,000 options to buy
@ $30.94, valued at
$1.9M
|
|
| 02/15/2022 |
4
| Kathiresan Sekar (CEO) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Granted 332,000 options to buy
@ $30.94, valued at
$10.3M
|
|
| 02/15/2022 |
4
| Bellinger Andrew (Chief Scientific Officer) has filed a Form 4 on Verve Therapeutics, Inc.|
Txns:
| Granted 125,000 options to buy
@ $30.94, valued at
$3.9M
|
|
|
|
|